Citius Oncology raises $36.5m, but can Lymphir convert rare cancer approval into commercial traction?
Lymphir has funding and FDA approval. Citius Oncology now faces the harder test of turning rare cancer access into real adoption.
Pharma & Biotech
Pharma & Biotech
How Soligenix is trying to turn tolerability and treatment logistics into a differentiated regulatory and commercial story
Soligenix published HyBryte versus Valchlor data in CTCL. Read what it changes for approval, adoption, and competitive positioning.